Proteomics analysis of human serum of patients with non‐small‐cell lung cancer reveals proteins as diagnostic biomarker candidates

Abstract

Non-small-cell lung carcinomas (NSCLC) is the most common type of lung cancer and it has a poor prognosis, because overall survival after 5 years is 20-25% for all stages.Thus, it is extremely important to increase the survival rate in the early stages NSCLC by focusing on novel screening tests of cancer identifying specific biomarkers expression associated with a more accurate tumor staging and patient prognosis. In this study, we focused our attention on quantitative proteomics of three heavily glycosylated serum proteins: AMBP, α2 macroglobulin, and SERPINA1. In particular, we analyzed serum samples from 20 NSCLC lung adenocarcinoma cancer patients in early and advanced stages, and 10 healthy donors to obtain a relative quantification through the MRM analysis of these proteins that have shown to be markers of cancer development and progression. AMBP, α2 macroglobulin, and SERPINA1 were chosen because all of them possess endopeptidase inhibitor activity and play key roles in cancer. We observe a variation in the expression of these proteins linked to the stage of the disease. Therefore, we believe that proteins like α2 macroglobulin, αmicroglobulin/bikunin, and SERPINA1 could be useful biomarkers for early detection of lung cancer and in monitoring its evolution. K E Y W O R D S α2 macroglobulin, AMBP, HPLC-MS/MS analysis, NSCLC, SERPINA1

Plasma Proteomics Analysis for Screening Anlotinib Responders in Non-small Cell Lung Cancer

“…Presently, proteomics-based liquid biopsy guided cancer treatment is still in early stage [19]. Studies have shown that the potential value of screen cancer biomarkers from blood via proteomics [19,25,26]. Our results suggested anlotinib-induced the alteration of plasma protein levels from responders may be used as alternative biomarkers.…”

“…Proteomic technology has been used in biomedical research widely since its development [17][18][19]. Ying Jiang et al found that proteomic could identify novel therapeutics targets for hepatocellular carcinoma [20].…”

“…Mark A Eckert et al suggested the metabolic regulator NNMT can be screened out via proteomics [21]. Furthermore, cancer biomarker screening based on proteomics has been introduced to clinical translational researches [19,22,23]. Due to complex architecture of anlotinib anti-angiogenic signaling pathway, proteomics can provide the platform just because of it can characterize proteins as a whole.…”

“…The development of liquid biopsy now is changing the clinical cancer therapeutic practice [19,24]. Presently, proteomics-based liquid biopsy guided cancer treatment is still in early stage [19].…”

“…The development of liquid biopsy now is changing the clinical cancer therapeutic practice [19,24]. Presently, proteomics-based liquid biopsy guided cancer treatment is still in early stage [19]. Studies have shown that the potential value of screen cancer biomarkers from blood via proteomics [19,25,26].…”